DRAP denies reports of medicine price hike, says supplies stable

In a clarification, the Drug Regulatory Authority of Pakistan has rejected reports of an increase in medicine prices, stating that no revision has been approved for essential drugs.

The pharma regulator said prices of medicines, including insulin and other life-saving drugs, remain unchanged and reports of a hike are based on misinterpretation.

The authority said prices cited in recent reports refer to maximum retail prices already printed on products manufactured in 2024 and 2025, and do not reflect any new increase.

DRAP said pharmaceutical companies are not allowed to implement unilateral price hikes for medicines listed under the National Essential Medicines List.

The authority added that it has reviewed the supply chain of medicines and medical devices and found availability to be stable for the coming months.

Officials said around 85 percent of medicines used in Pakistan are produced locally and are not affected by disruptions in global shipping or air routes.

DRAP has issued advisories to manufacturers to ensure contingency planning and diversify sourcing channels to maintain supply continuity.

The regulator also urged media organisations to verify information before publication to avoid public concern regarding availability and pricing of essential medicines.

DRAP said it will continue to monitor the sector to ensure uninterrupted access to medicines across the country.